Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.46 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28202486 | 0.98 | NOS3 (0.45) | NOS3NOS2NOS1EPHX2NAPRT | |
| Hydrochloric Acid SCHEMBL29857654 | 0.98 | NOS3 (0.45) | NOS3NOS2NOS1EPHX2NAPRT | |
| Formic Acid SCHEMBL31491080 | 0.89 | NAPRT (0.42) | NOS3NOS2NOS1EPHX2NAPRT | |
| Trifluoroacetic Acid SCHEMBL30699729 | 0.87 | NAPRT (0.49) | NAPRTHSD11B1L3MBTL1NFE2L2CTNNB1 | |
| SCHEMBL1255100 | 0.86 | SLC22A12 (0.43) | NOS3NOS2NOS1NAPRTHSD11B1 | |
| SCHEMBL9629714 | 0.83 | NOS3 (0.69) | NOS3NOS2HSD11B1NFE2L2LMNA | |
| SCHEMBL18191173 | 0.83 | NOS3 (0.43) | NOS3NOS2NOS1EPHX2NAPRT | |
| SCHEMBL9317262 | 0.82 | HSD11B1 (0.43) | HSD11B1ALDH1A1TDP1MAP4K4 | |
| Trifluoroacetic Acid SCHEMBL31491047 | 0.82 | NAPRT (0.44) | NAPRTHSD11B1L3MBTL1NFE2L2CTNNB1 | |
| SCHEMBL9629201 | 0.79 | NOS3 (0.42) | NOS3NOS2HSD11B1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-224252748-U | 2-Amino-3-trifluoromethyl pyridine apparatus for producing | 山东汇盟生物科技股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | claimed |
| EP-2991978-B1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F HOFFMANN LA ROCHE SA (CH) | 2025-08-20 | — | — | EP | claimed |
| WO-2025125665-A1 | FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | claimed |
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | claimed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | claimed |
| WO-2024040109-A2 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-22 | — | — | WO | claimed |
| EP-4305037-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-01-17 | — | — | EP | claimed |
| EP-4305038-A1 | KRAS G12D INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-01-17 | — | — | EP | claimed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2005048999-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| WO-2005049034-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| WO-2004024691-A1 | COX-2 INHIBITING PYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | claimed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-20030109551-A1 | Remedies or preventives for pulmonary insufficiency containing diaminotrifluoromethylpyridne derivatives | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2003-06-12 | — | — | US | claimed |
| EP-1252889-A1 | REMEDIES OR PREVENTIVES FOR PULMONARY INSUFFICIENCY CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2002-10-30 | — | — | EP | claimed |
| EP-0228846-B1 | AMINO-TRIFLUOROMETHYLPYRIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1992-04-22 | — | — | EP | claimed |
| US-4762928-A | PESTICIDES, MEDICINES | ISHIHARA SANGYO KAISHA LTD. (JP) | 1988-08-09 | — | — | US | claimed |
| EP-0228846-A1 | Amino-trifluoromethylpyridine compound and process for preparing the same | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1987-07-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109551-A1 | Remedies or preventives for pulmonary insufficiency containing diaminotrifluoromethylpyridne derivatives | CBR1, CBR3, WDR1 | NOS3 436/4885NOS2 633/4885NOS1 309/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | NOS3 642/4885NOS2 1040/4885NOS1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.